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Is Kenya Ready? Human Rights, COVID-19 and Vaccine Preparedness 
Kenya’s response to the global pandemic has so far been marked by two phases. The first was 
a rapid but coercive and badly thought-out lockdown that was challenged in court for 
infringing civil and political liberties.  
The second has been the much slower move to procure and distribute vaccines. This current 
phase also has human rights implications. Both Kenya’s constitution and international law 
require the state to take effective and prompt steps to protect and promote health. In relation 
to COVID-19, this includes ensuring vaccines are available, accessible without geographic or 
economic barriers, culturally acceptable within reason, and of sufficient quality.  
This may be an uphill challenge. According to the World Health Organisation’s (WHO) 
Vaccine Introduction Readiness Assessment Tool, African countries overall record an 
average score of 33% preparedness for COVID-19 vaccine roll-out against a recommended 
rate of 80%. 
How is Kenya faring, in terms of procurement (“availability”), distribution (“accessibility”) 
and uptake (“acceptability”)? 
Procurement 
Kenya requires 30 million doses to vaccinate 60% of its population, as recommended by the 
global public-private health partnership GAVI. Efforts at procurement, however, have been 
hindered, first by the Cabinet Secretary for Health’s doubts about the effectiveness of 
vaccines, and then by the delay in establishing a national taskforce for vaccine deployment 
until December 2020.  
Nonetheless, some progress has been made. Kenya is due to get 24 million doses of the 
Oxford/AstraZeneca vaccine through the joint WHO-GAVI COVAX facility, and a further 
12 million through bilateral engagements. It also stands to receive 10.8 million of the 270 
million doses the African Union (AU) acquired through its African Vaccine Acquisition Task 
Team (AVATT), though this will be slowed by the need for WHO approval. (A further 400 
million doses has been received by the AU but the structure for allocating them between 
countries has not yet been determined.)  
COVAX has promised to deliver the first 4 million doses by the end of February, but beyond 
that, Kenya worrying has no clear timelines for the delivery of its vaccines. It was set to start 
receiving the Oxford/AstraZeneca vaccines this month, but that plan has been thrown into 
disarray after the EU banned the export of vaccines produced within its member states. The 
situation of scarcity is worsened by the fact that the UK pre-signed contracts that prohibited 
exports until its domestic needs are met. This vaccine nationalism has given no regard to 
Kenya’s role in hosting trials of the vaccine. India has similarly blocked exports from its 
Serum Institute until at least 100 million doses are available for domestic use.  
These challenges in accessing the procured Oxford/Astrazeneca vaccines cannot be made up 
by the Pfizer/BioNTech or the Moderna vaccines as they require storage at -70 degrees 
Celsius which is not feasible on a mass scale in Kenya.  
Distribution  
Planning for distribution has been marked by similar delays. It was only on 29 January that 
Kenya’s Ministry of Health outlined the three phases of its vaccine roll-out. Phase one 
(February to June 2021) will target 1.25 Million health workers, security and immigration 
officials. Phase two (July 2021 to June 2022) will cover 9.7 million over-50s and over-18s 
with underlying health conditions. Phase three, run concurrently with phase two, will target 
4.9 million vulnerable people such as those in informal settlements.  
This broadly reflects WHO guidelines which prioritise groups most at risk. What it neglects 
are the realities of caring for vulnerable people, which is often done within families and by 
unpaid women.  
The Kenya-Gavi Technical Assistance Plan for 2021 sets out goals for several aspects of the 
vaccine delivery, but it remains aspirational. Experts warn in particular that failure to prepare 
for the vaccines’ transport to more remote counties as well as poor storage and administration 
could undermine preparation efforts.  
Inadequacy of personnel and training is also likely to pose a challenge. At the onset of the 
pandemic,  Kenya’s response was led by “Ebola Champions”: 155 medical practitioners sent 
to West Africa during the 2016 outbreak there. While this cadre, along with those 
experienced in the administration of other vaccines, will be invaluable, there has been no 
specific training in administering the COVID-19 vaccine to date. These shortcomings are 
compounded by an ongoing strike of healthcare workers in some counties. The unequal 
distribution of healthcare facilities in the country may also undermine distribution efforts in 
marginalised areas.  
Uptake 
These challenges may be compounded by the inability or unwillingness of certain population 
groups to attend vaccination centres. Poor terrain for travel, a suspicion of state-backed 
interventions, and the nomadic practices of some rural communities has inhibited the uptake 
of other vaccines and may do again. Pastoralists’ movement across international borders may 
lead them to miss out, while people in areas with high poverty levels may feel they cannot 
prioritise accessing the vaccine.  
Vaccine scepticism is also evident around the world. In Kenya, faith groups like Kavonokoya 
and Wakorino have long rejected modern medicine either on grounds of their religious beliefs 
and their preference for traditional medicine. These communities have resisted strategies such 
as wearing masks and are likely to refuse the COVID-19 vaccination as they have done with 
the polio vaccine.  
Conclusion: The International Context  
Kenya is not yet ready to deliver vaccines in sufficient quantity to those most at risk or to the 
population as a whole. While important steps have been taken, earlier government inaction, 
enduring structural discrimination, and widespread distrust of the state present major 
challenges.  
At the same time, Kenya’s fate has been crucially shaped by the decisions of states and 
corporate actors in the Global North. The UK, EU and US have all engaged in competitive 
national procurement strategies with little regard for the needs of vulnerable populations in 
the Global South. This is not simply a question of realpolitik, tempered by occasional charity 
in the interests of soft-power and diplomacy. It violates the legal obligation on states to allow 
each other to realise the right to health in their own territories, as the UN committee has 
recently emphasised.  
Put simply, buying up available supplies and barring their export, as well as enforcing 
applicable patents in a time of global emergency, amount to vaccine imperialism, inconsistent 
with a just international order based on human rights. 
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